 <h1>Imbruvica Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ibrutinib</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ibrutinib. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Imbruvica.</p><h2>In Summary</h2><p><b>Common side effects of Imbruvica include:</b> infection, anemia, neutropenia, thrombocytopenia, bruise, and cytopenia. <b>Other side effects include:</b> malignant neoplasm, malignant neoplasm of skin, subdural hematoma, gastrointestinal hemorrhage, and hematuria.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ibrutinib: oral capsule, oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ibrutinib (the active ingredient contained in Imbruvica) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ibrutinib:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>bladder pain</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>bloody or black, tarry stools</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>body aches or pain</li>
<li>chest pain</li>
<li>chills</li>
<li>confusion</li>
<li>cough</li>
<li>decreased frequency or amount of urine</li>
<li>difficult, burning, or painful urination</li>
<li>dizziness or lightheadedness</li>
<li>drowsiness</li>
<li>dry mouth</li>
<li>fainting</li>
<li>fast or irregular heartbeat</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>headache</li>
<li>hoarseness</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>itching</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>nausea</li>
<li>rapid weight gain</li>
<li>seizures</li>
<li>severe headache</li>
<li>severe stomach pain</li>
<li>sore throat</li>
<li>tightness of the chest</li>
<li>tingling of the hands or feet</li>
<li>troubled breathing</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>vomiting</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
<li>wrinkled skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Persistent non-healing sore</li>
<li>pink skin growth</li>
<li>reddish skin patch or irritated area</li>
<li>shiny skin bump</li>
<li>white, yellow or waxy scar-like area on the skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>dark urine</li>
<li>diarrhea</li>
<li>difficulty swallowing</li>
<li>general feeling of tiredness or weakness</li>
<li>hives, skin rash</li>
<li>joint pain, stiffness, or swelling</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>light-colored stools</li>
<li>muscle pain</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ibrutinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Belching</li>
<li>decreased appetite</li>
<li>difficulty having a bowel movement</li>
<li>heartburn or indigestion</li>
<li>indigestion</li>
<li>lack or loss of strength</li>
<li>muscle stiffness or spasms</li>
<li>small red or purple spots on the skin</li>
<li>stomach discomfort, upset, or pain</li>
<li>swelling or inflammation of the mouth</li>
</ul><p>
<!-- end oral capsule, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ibrutinib: oral capsule, oral tablet</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (17%)</p>
<p><b>Common</b> (1% to 10%): Atrial fibrillation, atrial flutter<sup>[Ref]</sup></p><h3>Hematologic</h3><p>-Lymphocytosis occurred in up to 77% of treated patients.  Typical onset of isolated lymphocytosis was within the first month of starting the drug and resolved approximately at 8 weeks.  </p>
<p>-Bleeding events occurred in up to 50% of treated patients.  Bleeding events ranged from minor hemorrhagic events such as petechiae and contusions to Grade 3 or higher bleeding events.  Approximately 6% of patients experienced a Grade 3 or higher bleeding event including cases of subdural hematoma, gastrointestinal bleeding, hematuria and post procedural hemorrhage</p>
<p>-Treatment-emergent Grade 3 or 4 cytopenias included neutropenia (19% to 29%), thrombocytopenia (5% to 17%), and anemia (0 to 9%).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Lymphocytosis (77%), decreased platelets (71%), decreased neutrophils (54%), bleeding events (all grades; approximately 50%), decreased hemoglobin (44%), neutropenia (29%), thrombocytopenia (17%)</p>
<p><b>Common</b> (1% to 10%): Bleeding events, anemia, febrile neutropenia</p>
<p><b>Uncommon</b> (less than 1%): Leukostasis </p>
<p><b>Very common</b> (10% or more): Upper respiratory tract infection (34%), urinary tract infection (14%), pneumonia (14%), skin infections (14%), sinusitis (13%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Anaphylactic shock (fatal), urticaria, angioedema<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Progressive multifocal leukoencephalopathy (PML)<sup>[Ref]</sup></p><p>Grade 3 or higher infections including urinary tract infection, pneumonia, skin infections, and sinusitis were reported.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (37%), arthralgia (23%), muscle spasms (19%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Blurred vision (10%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Elevated uric acid levels (40%), decreased appetite (21%), hyperuricemia (15%), dehydration (12%)</p>
<p><b>Frequency not reported</b>: Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Anxiety (10%), insomnia (10%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (14%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Very common</b> (10% or more): Second primary malignancies (10%)</p>
<p><b>Common</b> (1% to 10%): Non-melanoma skin cancer, carcinomas<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (up to 48%), dyspnea (up to 27%), sinusitis (up to 21%), cough (up to 19%), oropharyngeal pain (up to 15%), pneumonia (up to 15%), epistaxis (up to 11%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (41%), peripheral edema (35%), pyrexia (25%), asthenia (14%), chills (13%)</p>
<p><b>Frequency not reported</b>: Gait instability<sup>[Ref]</sup></p><h3>General</h3><p>The most commonly occurring adverse reactions (25% or more) included thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dizziness (21%), headache (19%), peripheral neuropathy (10%)</p>
<p><b>Common</b> (1% to 10%): Subdural hematoma </p>
<p><b>Frequency not reported</b>: Intracranial hemorrhage, lethargy<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (14%): Urinary tract infection </p>
<p><b>Common</b> (1% to 10%): Increased creatinine</p>
<p><b>Frequency not reported</b>: Renal failure (fatal and serious cases)<sup>[Ref]</sup></p><p>Fatal and serious cases of renal failure have been reported.  Increases in creatinine 1.5 to 3 times the upper limit of normal have been observed (9%).<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>petechiae (17%), contusion (11%), laceration (10%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (63%), nausea (31%), constipation (25%), abdominal pain (24%), vomiting (23%), stomatitis (21%), dyspepsia (13%)</p>
<p><b>Common</b> (1% to 10%): Dry mouth<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Imbruvica (ibrutinib)." Pharmacyclics Inc, Sunnyvale, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How long can you stay on Imbruvica (ibrutinib)?</li>
<li>How much does Imbruvica cost?</li>
<li>How quickly does Imbruvica (ibrutinib) work?</li>
<li>Is Imbruvica a chemotherapy drug?</li>
<li>Who makes Imbruvica?</li>
<li>What are the names of the BTK inhibitors?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Imbruvica (ibrutinib)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>35 Reviews</li>
<li>Drug class: BTK inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Imbruvica &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Waldenström Macroglobulinemia</li>
<li>Chronic Lymphocytic Leukemia</li>
<li>Non-Hodgkin's Lymphoma</li>
<li>Mantle Cell Lymphoma</li>
<li>Graft-versus-host disease</li>
<li>Lymphoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ibrutinib: oral capsule, oral tablet</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (17%)</p><p><b>Common</b> (1% to 10%): Atrial fibrillation, atrial flutter<sup>[Ref]</sup></p><h3>Hematologic</h3><p>-Lymphocytosis occurred in up to 77% of treated patients.  Typical onset of isolated lymphocytosis was within the first month of starting the drug and resolved approximately at 8 weeks.  </p><p>-Bleeding events occurred in up to 50% of treated patients.  Bleeding events ranged from minor hemorrhagic events such as petechiae and contusions to Grade 3 or higher bleeding events.  Approximately 6% of patients experienced a Grade 3 or higher bleeding event including cases of subdural hematoma, gastrointestinal bleeding, hematuria and post procedural hemorrhage</p><p>-Treatment-emergent Grade 3 or 4 cytopenias included neutropenia (19% to 29%), thrombocytopenia (5% to 17%), and anemia (0 to 9%).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Lymphocytosis (77%), decreased platelets (71%), decreased neutrophils (54%), bleeding events (all grades; approximately 50%), decreased hemoglobin (44%), neutropenia (29%), thrombocytopenia (17%)</p><p><b>Common</b> (1% to 10%): Bleeding events, anemia, febrile neutropenia</p><p><b>Uncommon</b> (less than 1%): Leukostasis </p><p><b>Very common</b> (10% or more): Upper respiratory tract infection (34%), urinary tract infection (14%), pneumonia (14%), skin infections (14%), sinusitis (13%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Anaphylactic shock (fatal), urticaria, angioedema<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Progressive multifocal leukoencephalopathy (PML)<sup>[Ref]</sup></p><p>Grade 3 or higher infections including urinary tract infection, pneumonia, skin infections, and sinusitis were reported.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (37%), arthralgia (23%), muscle spasms (19%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Blurred vision (10%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Elevated uric acid levels (40%), decreased appetite (21%), hyperuricemia (15%), dehydration (12%)</p><p><b>Frequency not reported</b>: Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Anxiety (10%), insomnia (10%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (14%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Very common</b> (10% or more): Second primary malignancies (10%)</p><p><b>Common</b> (1% to 10%): Non-melanoma skin cancer, carcinomas<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (up to 48%), dyspnea (up to 27%), sinusitis (up to 21%), cough (up to 19%), oropharyngeal pain (up to 15%), pneumonia (up to 15%), epistaxis (up to 11%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (41%), peripheral edema (35%), pyrexia (25%), asthenia (14%), chills (13%)</p><p><b>Frequency not reported</b>: Gait instability<sup>[Ref]</sup></p><h3>General</h3><p>The most commonly occurring adverse reactions (25% or more) included thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dizziness (21%), headache (19%), peripheral neuropathy (10%)</p><p><b>Common</b> (1% to 10%): Subdural hematoma </p><p><b>Frequency not reported</b>: Intracranial hemorrhage, lethargy<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (14%): Urinary tract infection </p><p><b>Common</b> (1% to 10%): Increased creatinine</p><p><b>Frequency not reported</b>: Renal failure (fatal and serious cases)<sup>[Ref]</sup></p><p>Fatal and serious cases of renal failure have been reported.  Increases in creatinine 1.5 to 3 times the upper limit of normal have been observed (9%).<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>petechiae (17%), contusion (11%), laceration (10%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (63%), nausea (31%), constipation (25%), abdominal pain (24%), vomiting (23%), stomatitis (21%), dyspepsia (13%)</p><p><b>Common</b> (1% to 10%): Dry mouth<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Imbruvica (ibrutinib)." Pharmacyclics Inc, Sunnyvale, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How long can you stay on Imbruvica (ibrutinib)?</li>
<li>How much does Imbruvica cost?</li>
<li>How quickly does Imbruvica (ibrutinib) work?</li>
<li>Is Imbruvica a chemotherapy drug?</li>
<li>Who makes Imbruvica?</li>
<li>What are the names of the BTK inhibitors?</li>
</ul><h2>More about Imbruvica (ibrutinib)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>35 Reviews</li>
<li>Drug class: BTK inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Imbruvica &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Waldenström Macroglobulinemia</li>
<li>Chronic Lymphocytic Leukemia</li>
<li>Non-Hodgkin's Lymphoma</li>
<li>Mantle Cell Lymphoma</li>
<li>Graft-versus-host disease</li>
<li>Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>